Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH)

Affiliations

¹ Department of Clinical Physiology/Nuclear Medicine, 239, RegionH: Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, DK-2650 Hvidovre, Denmark.

Comment

Jens H Henriksen et al. J Hepatol. 2008 Jan.

. 2008 Jan;48(1):174-6.

doi: 10.1016/j.jhep.2007.10.004. Epub 2007 Nov 5.

¹ Department of Clinical Physiology/Nuclear Medicine, 239, RegionH: Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, DK-2650 Hvidovre, Denmark.

No abstract available

Comment on

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE, Wolski K. Nissen SE, et al. N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21. N Engl J Med. 2007. PMID: 17517853
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group. Home PD, et al. N Engl J Med. 2007 Jul 5;357(1):28-38. doi: 10.1056/NEJMoa073394. Epub 2007 Jun 5. N Engl J Med. 2007. PMID: 17551159 Clinical Trial.